Whipple's Surgery (Pancreaticoduodenectomy)

Whipple's surgery, formally known as pancreaticoduodenectomy (PD), is one of the most complex and technically demanding operations in abdominal surgery. First described by Allen O. Whipple in 1935, it involves the en bloc removal of the head of the pancreas, the duodenum, the gallbladder, the lower common bile duct, and often the distal stomach (classic Whipple) or preservation of the pylorus (pylorus-preserving pancreaticoduodenectomy, PPPD). It is the standard curative operation for cancers of the pancreatic head, periampullary region (ampulla of Vater, distal bile duct, duodenum), and for selected benign conditions such as chronic pancreatitis with intractable head-dominant disease or large symptomatic IPMN involving the head.

The reconstructive phase of the operation — re-establishing continuity of the digestive and biliary tracts — is equally demanding. Three anastomoses are created: a pancreaticojejunostomy (or pancreaticogastrostomy) to join the pancreatic remnant to the jejunum; a hepaticojejunostomy to reconnect the bile duct to the bowel; and a gastrojejunostomy (or duodenojejunostomy in PPPD) for gastric drainage. The pancreaticojejunostomy is the most technically critical anastomosis, and its failure — postoperative pancreatic fistula (POPF) — is the most significant complication, occurring in 10–20% of cases and potentially causing serious secondary complications including haemorrhage and sepsis.

At experienced HPB centres, Whipple's surgery carries a mortality of less than 3–5% and a morbidity of 40–60% (predominantly minor complications). At our centre, meticulous surgical technique, dedicated anaesthesia, and robust postoperative care protocols ensure that patients recover safely and efficiently, with hospital stays typically of 10–14 days. Minimally invasive Whipple's surgery (laparoscopic or robotic) is increasingly offered to suitable patients, with benefits of reduced blood loss, lower wound complications, and faster recovery. Pathological staging of the resected specimen guides the decision for adjuvant chemotherapy, typically with gemcitabine/capecitabine or FOLFIRINOX regimens.